Biosense Webster Inc and Medtronic Inc have announced plans to collaborate to advance the care of patients with cardiac arrhythmias, also known as irregular heartbeats. Under the terms of the agreement, the two companies plan to collaborate on three key areas of interest: a clinical trial, a technology development initiative and educational programmes. The companies intend to design the clinical trial to create a new care pathway for identifying candidates most likely to have a successful ablation treatment outcome and increase the acceptance of ablation therapy.
In addition, the two companies will work together to advance patient care through a joint research and development programme. The companies plan to integrate specific technologies to provide novel, new solutions for the treatment of complex cardiac arrhythmias.